Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Lilla, Hámori"'
Autor:
Bálint Szeder, Júlia Tárnoki-Zách, Dóra Lakatos, Virág Vas, Gyöngyi Kudlik, Balázs Merő, Kitti Koprivanacz, László Bányai, Lilla Hámori, Gergely Róna, András Czirók, András Füredi, László Buday
Publikováno v:
Cells, Vol 8, Iss 11, p 1343 (2019)
Epithelial to mesenchymal transition (EMT) is a multipurpose process involved in wound healing, development, and certain pathological processes, such as metastasis formation. The Tks4 scaffold protein has been implicated in cancer progression; howeve
Externí odkaz:
https://doaj.org/article/84376eed26f24ff19d7331d4d3cfb4a9
Autor:
Flóra, Vajda, Eszter, Bajtai, Balázs, Gombos, Edina, Karai, Lilla, Hámori, Gergely, Szakács, András, Füredi
Publikováno v:
Magyar onkologia. 65(2)
There are about 14 million new cancer cases and 8 million deaths every year. Every second man and one in every three women will get cancer during their lifetimes. Following decades of steady increase, death rates have stabilized due to increased awar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::a62edc3b2d6535a55476acedf2ecbc77
https://pubmed.ncbi.nlm.nih.gov/34081765
https://pubmed.ncbi.nlm.nih.gov/34081765
Autor:
Lilla, Hámori, Gyöngyi, Kudlik, Kornélia, Szebényi, Nóra, Kucsma, Bálint, Szeder, Ádám, Póti, Ferenc, Uher, György, Várady, Dávid, Szüts, József, Tóvári, András, Füredi, Gergely, Szakács
Publikováno v:
International Journal of Molecular Sciences
Breast cancer is the most commonly occurring cancer in women and the second most common cancer overall. By the age of 80, the estimated risk for breast cancer for women with germline BRCA1 or BRCA2 mutations is around 80%. Genetically engineered BRCA
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::8978cf44f402fb6799e729275cd84390
https://pubmed.ncbi.nlm.nih.gov/32053991
https://pubmed.ncbi.nlm.nih.gov/32053991
Autor:
FLÓRA, VAJDA, ESZTER, BAJTAI, BALÁZS, GOMBOS, EDINA, KARAI, LILLA, HÁMORI, GERGELY, SZAKÁCS, ANDRÁS, FÜREDI
Publikováno v:
Magyar Onkologia; 2021, Vol. 65 Issue 2, p176-187, 12p
Autor:
József Tóvári, Lilla Hámori, Mihály Cserepes, Gergely Szakács, Kornélia Szebényi, Pál Szabó, Péter Vajdovich, András Füredi, Veronika Nagy, Edina Karai, Szilárd Tóth, Tímea Imre, Dávid Szüts
Publikováno v:
Journal of controlled release : official journal of the Controlled Release Society. 261
Success of cancer treatment is often hampered by the emergence of multidrug resistance (MDR) mediated by P-glycoprotein (ABCB1/Pgp). Doxorubicin (DOX) is recognized by Pgp and therefore it can induce therapy resistance in breast cancer patients. In t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::81da6fb2431d7717c3d410cbaace573f
https://pubmed.ncbi.nlm.nih.gov/28700899
https://pubmed.ncbi.nlm.nih.gov/28700899